Metyloprednizolon podawany doustnie lub dożylnie w leczeniu rzutu stwardnienia rozsianego – komentarz redakcyjny do artykułu Emmanuelle Le Page i wsp. pt.: Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial (Lancet 2015; 386: 974–981)

• Authors: Karol Jastrzębski
• Languages of publication: PL

Discipline

• MEDICINE: MEDICINE

• Journal: Aktualności Neurologiczne
• Year: 2016
• Volume: 16
• Issue: 2
• Pages: 109-111

Contributors

author

Karol Jastrzębski

• Klinika Neurologii i Udarów Mózgu, Uniwersytet Medyczny w Łodzi, Łódź, Polska,

References

• Alam SM, Kyriakides T, Lawden M et al.: Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219–1220.
• Barkhof F, Hommes OR, Scheltens P et al.: Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219–1222.
• Brusaferri F, Candelise L: Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435–442.
• Burton JM, O’Connor PW, Hohol M et al.: Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12: CD006921.
• Chen TC, Mackic JB, McComb JG et al.: Cellular uptake and transport of methylprednisolone at the blood-brain barrier. Neurosurgery 1996; 38: 348–354.
• Derendorf H, Möllmann H, Rohdewald P et al.: Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther 1985; 37: 502–507.
• Durelli L, Cocito D, Riccio A et al.: High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238–243.
• Hayball PJ, Cosh DG, Ahern MJ et al.: High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol 1992; 42: 85–88.
• Karampampa K, Gustavsson A, Miltenburger C et al.: Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012a; 18 (Suppl): 7–15.
• Karampampa K, Gustavsson A, Miltenburger C et al.: Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012b; 19: e11–e25.
• Le Page E, Veillard D, Laplaud DA et al.; COPOUSEP investigators; West Network for Excellence in Neuroscience: Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015; 386: 974–981.
• Miller DM, Weinstock-Guttman B, Béthoux F et al.: A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000; 6: 267–273.
• Milligan NM, Newcombe R, Compston DA: A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511–516.
• O’Brien JA, Ward AJ, Patrick AR et al.: Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3: 17.
• Richert ND, Ostuni JL, Bash CN et al.: Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001; 7: 49–58.
• Rohatagi S, Barth J, Möllmann H et al.: Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol 1997; 37: 916–925.
• Sellebjerg F, Barnes D, Filippini G et al.; EFNS Task Force on Treatment of Multiple Sclerosis Relapses: EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005; 12: 939–946.
• Tomita M, Watanabe A, Fujinaga I et al.: Nonlinear absorption of methylprednisolone by absorptive and secretory transporters. Int J Pharm 2010; 387: 1–6.
• Zivadinov R, Zorzon M, De Masi R et al.: Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci 2008; 267: 28–35.

• Document Type: research_note